Month 60 Outcomes After Treatment Initiation With Anti–Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal or Hemiretinal Vein Occlusion

To investigate 5-year outcomes in eyes initially treated with aflibercept or bevacizumab for macular edema due to central retinal or hemiretinal vein occlusion. Long-term follow-up (LTF) after a randomized clinical trial from 64 centers in the United States. Participants were followed up to 60 month...

Full description

Saved in:

Bibliographic Details
Published in:	American journal of ophthalmology Vol. 240; pp. 330 - 341
Main Authors:	Scott, Ingrid U., VanVeldhuisen, Paul C., Oden, Neal L., Ip, Michael S., Blodi, Barbara A.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.08.2022 Elsevier Limited
Subjects:	Angiogenesis Inhibitors Bevacizumab - therapeutic use Diabetes Diabetic retinopathy Edema FDA approval Humans Intravitreal Injections Lasers Macular Edema - diagnosis Macular Edema - drug therapy Macular Edema - etiology Medical records Monoclonal antibodies Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Recombinant Fusion Proteins Retinal Vein Occlusion - complications Retinal Vein Occlusion - diagnosis Retinal Vein Occlusion - drug therapy Tomography, Optical Coherence Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors
ISSN:	0002-9394, 1879-1891, 1879-1891
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!